It has been reported that CDK12 and HER2 were frequently co-amplified in CRC, and inhibition of CDK12 can enhance the sensitivity of CRC cells to lapatinib, an anti-HER2 tyrosine kinase inhibitor (TKI) [53]. The gene discussed is CDK12; the disease is colorectal carcinoma.